Search the Newsreel

Beta Bionics (NASDAQ:BBNX) Shares Up 13.7% - Should You Buy?

Beta Bionics (NASDAQ:BBNX) saw its shares surge by 13.7% to $16.05, trading above its 50-day and 200-day moving averages, though its high beta of 3.13 indicates significant volatility. Analysts hold a "Moderate Buy" consensus with a $20.10 price target, despite one firm issuing a …

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported a significant increase in Q2 2026 net sales to $32.0 million, up from $23.2 million a year prior, primarily driven by its iLet insulin delivery device and single-use consumables. Despite this growth, the company continues to experience substantial losses, …

Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31

Beta Bionics, Inc. (BBNX) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.36, beating estimates by $0.20, and revenue of $32.01M, surpassing expectations by $533.03K with a 37.76% year-over-year increase. The slide deck was released in conjunction with the company's earnings …

A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4

This article provides an overview of recent analyst ratings for Beta Bionics (BBNX.US), highlighting a forecast range for its stock price between $15.5 and $30.4. It appears to be a summary of current market sentiment regarding the company's valuation.

Beta Bionics Earnings Call Highlights Growth And Risks

Law firm probes Beta Bionics for possible misleading growth claims affecting investors

Johnson Fistel, PLLP is investigating Beta Bionics for potential securities law violations due to allegedly misleading statements about its growth and new patient starts. This probe was triggered by Beta Bionics' disclosure of significantly slower growth in new patient starts for Q4 2025, which …

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

Johnson Fistel, PLLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations after the company disclosed slower new patient start growth for Q4 2025, which fell below analyst expectations and showed significant deceleration from the previous quarter. The law firm is …

Healthcare of Ontario Pension Plan Trust Fund Lowers Stake in Beta Bionics, Inc. $BBNX

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

Beta Bionics reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase year-over-year, with strong growth in its Pharmacy Benefit Plan channel. The company initiated a pivotal trial for its iLet device in type 2 diabetes and updated …

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Beta Bionics, Inc. (BBNX) reported a Q2 loss of $0.53 per share, exceeding the Zacks Consensus Estimate of a $0.62 loss, and revenues of $32.01 million, surpassing estimates by 2.07%. Despite outperforming earnings and revenue expectations, the company's shares have declined by 48.2% year-to-date, …

Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation

Beta Bionics (NASDAQ:BBNX) has a solid cash runway of about 3.3 years, holding US$200 million in cash against an annual burn of US$61 million. Despite a slight increase in cash burn, the company's strong revenue growth of 58% and low cash burn relative to …

UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating

UBS has adjusted its price target for Beta Bionics (BBNX) to $22, down from $24, while maintaining a Buy rating on the stock. This update reflects a revised valuation perspective for the medical device company, which specializes in insulin delivery systems for people with …

Earnings To Watch: Beta Bionics Inc (BBNX) Reports Q2 2026 Result

Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data …

Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism

The fair value estimate for Beta Bionics (BBNX) has decreased from US$31.30 to US$19.80 per share, aligning more closely with current analyst price targets. This adjustment reflects a balance between continued optimism for their iLet product and planned Mint launch, and broader medtech sector …

Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Beta Bionics Inc (BBNX) stock, focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years, with no dividend data currently available. The page also presents current …

Beta Bionics Inc (BBNX) Institutional Confidence

Beta Bionics Inc (BBNX) has an institutional shareholding score of 10.00, ranking it 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 4.12% quarter-over-quarter to 110.51%. Frank Sands is the largest institutional shareholder, holding 3.08 million shares, representing 8.01% of …

Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group

A Schedule 13G SEC filing reveals that Divisadero Street Capital Management, LP, along with William Zolezzi and related entities, has acquired a significant beneficial ownership of 3,072,985 shares in Beta Bionics, Inc. (BBNX), representing 6.9% of the common stock. This filing indicates shared voting …

BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200

Beta Bionics Inc. (BBNX) is a commercial-stage medical device company focused on solutions for insulin-requiring diabetes patients, particularly with its iLet Bionic Pancreas. The company exhibits strong fundamentals with significant revenue growth and high institutional ownership, though its stock performance has been mixed recently. …

Beta Bionics (BBNX) price target decreased by 11.15% to 20.99

This article reports that Beta Bionics (BBNX) has experienced an 11.15% decrease in its price target, bringing it down to $20.99. No further details are provided regarding the reasons behind this adjustment or the analyst responsible. The content is very brief and lacks additional …

BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0

Goldman Sachs has maintained its 'Buy' rating for Beta Bionics (BBNX) and raised the price target to $19.00 from $17.00, reflecting optimism about the company's growth, particularly its iLet Bionic Pancreas product. Despite this positive analyst outlook, BBNX has a low GF Score™ of …